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ABSTRACT  
Orodispersible tablets (ODTs), also known as fast melt, quick melts, fast disintegrating have the unique property of disintegrating in the mouth 
in seconds without chewing and the need of water. Oral bioavailability of Atorvastatin Calcium is low (14%) and shows extensive intestinal 
clearance and first-pass metabolism, which is the main cause for the low systemic availability. In the present work, orodispersible tablets of 
Atorvastatin calcium were prepared by direct compression method using Hibiscus rosa sinesis mucilage as natural superdisintegrant with a 
view to enhance patient compliance and to avoid hepatic first pass metabolism and to improve its bioavailability. The prepared batches of 
tablets were evaluated for hardness, friability, drug content uniformity, wetting time, water-absorption ratio and in-vitro dispersion time. 
Short-term stability studies on the promising formulation indicated that there are no significant changes in drug content and in vitro dispersion 
time. 
Keywords: Orodispersible tablet, Atorvastatin Calcium, lipid-lowering agent, Superdisintegrant, Hibiscus Rosa Sinensis, Bioavailability, 
solubility.   
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INTRODUCTION 
Oral delivery is current standard in the pharmaceutical 
industry wherever it is regarded as the safest, most suitable 
and most economical method of drug delivery. The oral 
cavity is an attractive site for the administration of drugs 
because of ease of administration. 
Oro-dispersible drug delivery system are Novel Drug 
Delivery techniques that make the tablets disintegrate in the 
mouth without chewing and water, and immediate release 
and enhanced bioavailability, with better patient compliance. 
Recently, the European Pharmacopeia adopted the term 
orodispersible tablet for a tablet that disperses or 
disintegrates within a minute or second in the mouth before 
swallowing.  
United States Food and Drug Administration (FDA) defined 
Oro-dispersible tablet as “a solid dosage form containing 
medicinal substances or active ingredient which disintegrate 
or dissolve rapidly within seconds when placed upon the 
tongue.  
Oro-dispersible tablets have a quick dissolution and rapid 
absorption which provide rapid onset of action. Moreover, 
drug candidates that undergo pregastric absorption when 
formulated as ODTs may oral bioavailability of drug is 
enhanced by avoiding the hepatic first pass metabolism. It 
provides good stability, accurate dosing, easy of 
manufacturing. Oro-dispersible tablets are made by a direct 
compression method using super Disintegrate as an 
important component. 
MATERIAL AND METHODS  
Materials 
Atorvastatin calcium was obtained as a gift sample from 
Yarrowchem Products (Mumbai). Beta-cyclodextrin was 
obtained as a gift sample from Alkem laboratories Ltd 
(Mumbai). Microcrystalline Cellulose, Mannitol, Magnesium 
Stearate, Talc, Ethanol, Methanol and Silica gel-G, Lobachem 
Pvt. Ltd. Aspartame, Potassium Dihydrogen Phosphate, 
Sodium hydroxide and Hydrochloric acid were purchased 
from Lobachem and Merck Pvt Ltd. 
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Methods 
Drug Characterization  
Melting point determination 
Capillary tube was taken and one end was sealed by heating. 
Capillary tube was filled with drug powder upto 2-3mm high. 
The capillary tube was putted inside melting point apparatus 
and temperature was increased slowly. The temperature was 
noted when the drug gets starts melting and again noted 
when drugs completely melted. 
UV Spectroscopy 
50mg of drug was weighed and was dissolved in 50ml of 
methanol (1mg/ml). 10ml of this solution was withdrawn 
and volume was made up to 100ml. Appropriate dilutions 
were made with methanol to give concentration of 10 μg/ml, 
scanned in UV range from 200- 400nm, which could be 
utilized for analysis and spectrum was recorded. 
Calibration curve  
Accurately weighed 50mg of Atorvastatin Calcium was 
transferred into a 500ml volumetric flask & dissolved in 
phosphate buffer 6.8. Then sonicated for 15 minute and the 
volume was made up with phosphate buffer pH 6.8 to obtain 
a 100µg/ml stock solution of Atorvastatin Calcium.  
 
Fig. No. 1 Lambda Max of Atorvastatin Calcium 
Solubility studies 
An excess amount of prepared Atorvastatin-β-cyclodextrin 
inclusion complex at different concentration (1:3, 1:4, 1:5) 
were separately dissolved in 5ml phosphate buffer pH 6.8 in 
vials and sealed properly and stirred continuously. The 
process was repeated until saturation solubility of inclusion 
complex. The solution was kept for 24 hours at room 
temperature. Then solution was filtered. The adequately 
diluted with phosphate buffer pH 6.8. Then solution was 
analyzed by using UV-visible spectrophotometer at 
245.40nm.
  
Table no.1: Solubility data of Atorvastatin Calcium in different mediums: 
S.NO. Solvent 
 
Solubility (mg/ml) 
Mean±SD (n=3) 
Inference 
1 Methanol 30.106±2.186 Soluble 
2 Phosphate buffer pH 6.8 0.184±0.001 Very Slightly soluble 
3 pH 1.2 HCl buffer 0.108±0.007 Very Slightly soluble 
4. Water 0.578±0.010 Slightly soluble 
 
Formulation 
 Solubility enhancement by Inclusion Complex 
An excess amount of prepared Atorvastatin-β-cyclodextrin 
inclusion complex at different concentration (1:3, 1:4, 1:5) 
were separately dissolved in 5ml phosphate buffer pH 6.8 in 
vials and sealed properly and stirred continuously. The 
process was repeated until saturation solubility of inclusion 
complex. The solution was kept for 24 hours at room 
temperature then solution was filtered. The solubility was 
determined by using UV- Spectroscopy. 
 
Table no. 2 
S.No. Phosphate buffer pH 6.8 Solubility (mg/ml) 
Mean±SD (n=3) 
Inference 
1 Pure drug 0.184±0.001 Very Slightly  Soluble 
2 Drug:β-CD (1:3) 0.471±0.004 Slightly Soluble 
3 Drug:β-CD (1:4) 0.694±0.008 Slightly Soluble 
4 Drug:β-CD (1:5) 0.840±0.012 Slightly Soluble 
 
 
 Experimental design 
A two factor three level factorial design (32) was used for the 
formulation optimization of orodispersible tablet of 
Atorvastatin and experimental trials are performed at all 9 
possible formulation. In which the amount of β-cyclodextrin 
(X1) and Hibiscus Rosa- Senesis mucilage (X2) were selected 
as independent variables (factor) varied at three different 
level: low(-1), medium(0), and high(+1) levels. 
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Table no. 3 
 
Preparation of Atorvastatin Calcium Fast Disssolving 
tablet by Direct compression method 
Orodispersible tablet of Atorvastatin were prepared by 
direct compression method. Weighed all the ingredients 
accurately according to the table no.3. All the ingredients 
except Talc, Magnessium sterate were mixed step by step 
and trituration was continued for 15 minute, and passed 
through sieve no. #60. Subsequently talc, magnesium 
stearate mixed at last & again mixed. The powder was 
compressed using multistation tablet punching machine 
(Aidmach Pvt. Ltd.) with 8mm flat punch, B-tooling and 
corresponding dies. 
Evaluation of Tablet 
 Weight variation 
Randomly, twenty tablets were selected after compression 
and the mean weight was determined. None of the tablets 
deviated from the average weight by more than ±7.5% 
(USPXX). 
 Thickness 
Thickness of tablet was determined by using vernier calliper 
(Mitutoya, Model CD-6 CS, Japan). 
 Hardness 
The crushing strength of the tablets was measured using a 
Monsanto hardness tester (Sheetal Scientific Industries, 
Mumbai, India). Three tablets from each formulation batch 
were tested randomly and the average reading noted. 
 Friability 
Twenty tablets were weighed and placed in a Roche 
friabilator (Electrolab, India). Twenty reweighed tablets 
were rotated at 25 rpm for 4 min. The tablets were then 
dedusted and reweighed and the percentage of weight loss 
was calculated. The percentage friability of the tablets were 
measured as per the following formula,  
Percentage friability       = Initial weight-Final weight x 100 
            Initial weight 
 Wetting time 
A piece of circular tissue paper (8cm) folded twice was 
placed in a Petri dish (Internal Diameter = 9cm) containing 
10 ml of buffer solution simulating saliva pH 6.8. A tablet 
was placed on the paper and the time taken for complete 
wetting was noted. Three tablets from each formulation 
were randomly selected and the average wetting time was 
noted. The results are tabulated in Table 6. 
 Water absorption ratio 
A piece of tissue paper folded twice was placed in a small 
petri dish containing 6 ml of water. A tablet was put on the 
tissue paper and allowed to completely wet. The wetted 
tablet was the reweighed. Water absorption ratio, R was 
determined using following equation- 
R = 100 × Wa-Wb/Wa 
Where, Wa = Weight of tablet after water absorption 
Wb = Weight of wetted tablet before water absorption  
 Disintegration Time 
One tablet was introduced into each tube and disc was 
added to each tube. The assembly was introduced in the 
beaker containing purified water. The apparatus operated 
until the tablet completely disintegrate. The time was noted 
down until the tablets completely disintegrate. The 
assembly was removed from water. 
 Dissolution Study 
In vitro release of Atorvastatin calcium  from tablets was 
monitored by using 900 ml of simulated intestinal fluid, SIF 
(USP phosphate buffer solution, pH 6.8) at 37±0.50C and 50 
rpm using programmable dissolution tester [Paddle type, 
model TDT-08L, Electrolab, (USP), India]. 5 ml Aliquots were 
withdrawn at one minute time intervals and were 
replenished immediately with the same volume of fresh 
buffer medium. Aliquots, following suitable dilutions, were 
assayed spectrophotometrically (UV- 1700, Shimadzu, Japan) 
at 245.5 nm.   
RESULT AND DISCUSSION 
Mouth dissolving drug delivery is rapidly gaining acceptance 
as an important drug delivery technology. In such drug 
delivery, different dosage forms disintegrate rapidly in the 
patient’s mouth within a minute and can be gulped easily 
without need of water. This rapid disintegration can be 
achieved by use of high levels of disintegrate and/or 
effervescent agents along with water soluble diluents. Hence, 
it offers increased patient compliance and convenience.  
orodispersible tablet  of Atorvastatin calcium was 
formulated. Total nine batches were prepared for 
orodispersible formulation. All the formulations were 
subjected to evaluation, Tablet weight varied from 110 to 
120 mg, and thickness 3 to 4.1 mm. All the tablets exhibited 
friability values between 0.5 to 0.8, all tablets disintegrated 
in less than 1 minute. The drug released at the time interval 
of 30 minutes upto 97.5% of batch F9.  
 
 
S. 
No 
Name of ingredients F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
F4 
(mg) 
F5 
(mg) 
F6 
(mg) 
F7 
(mg) 
F8 
(mg) 
F9 
(mg) 
1. Drug (Atorvastatin) 10 10 10 10 10 10 10 10 10 
2. β-cyclodextrin 30 30 30 40 40 40 50 50 50 
3. 
Hibiscus Rosa- Senesis 
Mucilage 
4 6 8 10 12 14 16 18 20 
4. Microcrystalline cellulose 120 120 120 120 120 120 120 120 120 
5. Mannitol 40 40 40 40 40 40 40 40 40 
6. Aspartame 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
7. Magnessium Stearate 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 
8. Talc 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 
Gupta
 
et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(6):90-94 
ISSN: 2250-1177                                                                                  [93]                                                                                 CODEN (USA): JDDTAO 
Table no. 4 Evaluation of Flow properties of powder (Drug excipient mixture) 
Formulation Bulk density 
(gm/ml) 
(n=3) 
Mean±SD 
Tapped density 
(gm/ml) 
Mean±SD 
Carr's index (%) 
(n=3) 
Mean±SD 
Angle of repose 
(o) (n=3) 
Mean±SD 
Hausner's 
ratio 
(n=3) 
Mean±SD 
MD1 0.314±0.004 0.368±0.004 14.635±1.503 25.406±0.374 1.170±0.026 
MD2 0.299±0.002 0.358±0.003 14.634±1.004 29.333±1.106 1.166±0.015 
MD3 0.288±0.002 0.345±0.003 16.323±1.047 27.606±0.525 1.186±0.015 
MD4 0.332±0.003 0.385±0.006 13.907±0.852 26.966±0.450 1.16±0.01 
MD5 0.307±0.003 0.363±0.002 15.260±1.695 25.59±0.213 1.176±0.020 
MD6 0.293±0.003 0.355±0.003 17.360±1.663 27.4±0.500 1.206±0.025 
MD7 0.344±0.003 0.402±0.004 14.414±0.402 26.74±0.767 1.166±0.005 
MD8 0.326±0.003 0.376±0.003 13.354±1.494 30.6±0.888 1.15±0.02 
MD9 0.298±0.002 0.330±0.001 9.787±0.459 26.633±0.709 1.103±0.005 
 
Table no. 5 Determination of physicochemical properties of orodispersible tablet 
Formulation Weight variation 
(mg) (n=3) 
Mean±SD 
Hardness 
(Kg/cm2) 
(n=3) 
Mean±SD 
Friability 
(%) 
(n=3) 
Mean±SD 
MD1 210.16±0.378 2.6±0.264 0.460±0.027 
MD2 211.75±0.312 2.4±0.173 0.750±0.047 
MD3 214±0.938 3.0±0.057 0.460±0.045 
MD4 223±0.301 2.9±0.152 0.672±0.045 
MD5 232±2.13 3.0±0.1 0.346±0.043 
MD6 233±0.28 3.0±0.057 0.343±0.043 
MD7 246.58±0.56 3.0±0.057 0.349±0.023 
MD8 247.83±1.05 3.1±0.1 0.361±0.040 
MD9 251.06±0.17 3.1±0.057 0.358±0.040 
 
Table no. 6 Other Evaluation parameters 
Formulation Disintegration 
Time (sec) 
  (n=3) 
Mean±SD 
Drug Content 
(%) 
(n=3) 
Mean±SD 
Wetting time 
(sec) 
(n=3) 
Mean±SD 
Water absorption 
Ratio (%) (n=3) 
Mean±SD 
MD1 42±1.05 91.833±0.233 32.7±0.590 55.97±3.63 
MD2 38±1.86 93.36±0.356 31.37±0.580 49.01±3.59 
MD3 37±1.93 95.84±1.362 30.05±0.040 42.18±3.13 
MD4 35±1.28 92.19±0.583 32.38±0.540 46.75±1.34 
MD5 30±1.25 99.25±0.470 29.71±0.546 30.3±1.56 
MD6 33±1.36 96.85±0.584 31.06±0.015 35.90±0.65 
MD7 45±1.68 95.76±0.466 33.38±0.580 36.83±0.61 
MD8 36±1.26 95.60±1.151 34.69±0.534 40.42±0.61 
MD9 39±1.48 93.73±1.113 35.06±0.015 41.96±0.60 
 
Table no. 7 Invitro drug release study 
Time 
(in min 
% Cumulative  drug Release (Mean±SD) (n=3) 
MD1 MD2 MD3 MD4 MD5 MD6 MD7 MD8 MD9 
0 0 0 0 0 0 0 0 0 0 
5 
11.4±3.20 16.9± 
3.16 
21.84± 
4.35 
28.83± 
2.11 
27.44± 
2.41 
30.24± 
3.27 
21.15±3.
21 
23.94± 
3.21 
21.84± 
2.44 
10 
214± 
1.19 
25.3± 
1.60 
37.2± 
2.11 
34.2± 
2.11 
35.1± 
2.07 
39.99± 
3.20 
28.83± 
2.11 
34.44± 
4.35 
28.14± 
3.20 
15 
34.41± 
3.16 
40.0± 
1.20 
46.29± 
2.44 
44.21± 
3.18 
46.98± 
3.21 
44.87± 
1.280 
41.14± 
2.07 
43.51± 
3.62 
33.71± 
3.16 
20 
44.2± 
4.37 
53.9± 
5.52 
57.45± 
6.41 
50.51± 
4.81 
56.07± 
2.07 
55.34±3.2
2 
53.24± 
2.45 
56.76± 
1.95 
47± 
3.21 
25 
58.14± 
2.07 
67.9± 
5.25 
63.72± 
4.34 
67.92± 
3.20 
73.14± 
2.14 
62.24±1.9
6 
75.59± 
3.21 
72.83± 
2.07 
68.61± 
2.11 
30 
90.94± 
3.17 
86.0±1.2
4 
 
89.55± 
3.58 
88.13± 
3.19 
95.84± 
2.08 
84.66±3.2
0 
86.76± 
1.24 
92.34± 
4.34 
93.72± 
2.09 
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Fig no. 2 Invitro drug release of orodispersable  tablet 
Table no. 8 Stability studies 
S.No. Parameter After 30 days Inference 
1. Weight variation 229.33±0.574 Within Limit 
2. Hardness 3.03±0.055 Within Limit 
3. Drug content 99.36±0.568 Within Limit 
4. Wetting time 27.66±0.364 Within Limit 
5. Water absorption ratio 33.66±0.475 Within Limit 
6. Disintegration 33.48±0.575 Within Limit 
 
 
CONCLUSION 
The present study was carried out to prove that 
Orodispersible tablet of Atorvastatin calcium can be 
formulated. The concept explains that formulated tablets 
avoids hepatic first pass metabolism and improves its 
bioavailability.  
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